JP2010540446A - シクロスポリン組成物 - Google Patents

シクロスポリン組成物 Download PDF

Info

Publication number
JP2010540446A
JP2010540446A JP2010525937A JP2010525937A JP2010540446A JP 2010540446 A JP2010540446 A JP 2010540446A JP 2010525937 A JP2010525937 A JP 2010525937A JP 2010525937 A JP2010525937 A JP 2010525937A JP 2010540446 A JP2010540446 A JP 2010540446A
Authority
JP
Japan
Prior art keywords
composition
cyclosporin
rabbit
drop
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540446A5 (enExample
Inventor
リチャード・エス・グレアム
ウォルター・エル・ティエン
アイリーン・モーガン
レット・シフマン
デイビッド・エイ・ホランダー
メイッサ・アッター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2010540446A publication Critical patent/JP2010540446A/ja
Publication of JP2010540446A5 publication Critical patent/JP2010540446A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2010525937A 2007-09-20 2008-09-18 シクロスポリン組成物 Pending JP2010540446A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/858,200 US20080146497A1 (en) 2006-07-25 2007-09-20 Cyclosporin Compositions
PCT/US2008/076756 WO2009099467A2 (en) 2007-09-20 2008-09-18 Cyclosporin compositions

Publications (2)

Publication Number Publication Date
JP2010540446A true JP2010540446A (ja) 2010-12-24
JP2010540446A5 JP2010540446A5 (enExample) 2011-11-10

Family

ID=39528114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525937A Pending JP2010540446A (ja) 2007-09-20 2008-09-18 シクロスポリン組成物

Country Status (12)

Country Link
US (1) US20080146497A1 (enExample)
EP (1) EP2190407B1 (enExample)
JP (1) JP2010540446A (enExample)
KR (1) KR20100091946A (enExample)
CN (1) CN101835463A (enExample)
AU (1) AU2008349774A1 (enExample)
BR (1) BRPI0816995A2 (enExample)
CA (1) CA2700182A1 (enExample)
IL (1) IL204614A0 (enExample)
MX (1) MX2010003045A (enExample)
RU (1) RU2010112472A (enExample)
WO (1) WO2009099467A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510921A (ja) * 2012-03-22 2015-04-13 ラボラトワール テアＬａｂｏｒａｔｏｉｒｅｓ Ｔｈｅａ シクロスポリンａに基づく水性点眼溶液

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
WO2010127301A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Method of treating allergic conjunctivitis with cyclosporin compositions
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
RU2014129268A (ru) * 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
EP3169308B1 (en) * 2014-07-18 2021-01-27 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
RU2762767C1 (ru) * 2020-09-15 2021-12-22 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Министерства здравоохранения Российской Федерации Способ определения тактильной чувствительности роговицы

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485921A (en) * 1987-06-04 1989-03-30 Sankyo Co Cyclosporin preparation
JPH03503159A (ja) * 1987-09-03 1991-07-18 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド 眼科用サイクロスポリン組成物
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485921A (en) * 1987-06-04 1989-03-30 Sankyo Co Cyclosporin preparation
JPH03503159A (ja) * 1987-09-03 1991-07-18 ユニバーシティ　オブ　ジョージア　リサーチ　ファウンデーション，インコーポレイテッド 眼科用サイクロスポリン組成物
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013026220; ＲＡＯ，Ｓ．Ｎ．: 'Ｔｒｅａｔｍｅｎｔ　ｏｆ　ｈｅｒｐｅｓ　ｓｉｍｐｌｅｘ　ｖｉｒｕｓ　ｓｔｒｏｍａｌ　ｋｅｒａｔｉｔｉｓ　ｕｎｒｅｓｐｏｎｓｉｖｅ　ｔｏ　ｔｏｐｉｃａｌ　ｐｒｅｄｎｉｓｏｌｏｎｅ　１％　ｗｉｔｈ　ｔｏｐ' Ａｍ　Ｊ　Ｏｐｈｔｈａｌｍｏｌ Ｖｏｌ．１４１，　Ｎｏ．４, 2006, ｐ．７７１-２ *
JPN6013026221; ＨＥＩＬＩＧＥＮＨＡＵＳ，Ａ．　ｅｔ　ａｌ: 'Ｔｒｅａｔｍｅｎｔ　ｏｆ　ＨＳＶ-１　ｓｔｒｏｍａｌ　ｋｅｒａｔｉｔｉｓ　ｗｉｔｈ　ｔｏｐｉｃａｌ　ｃｙｃｌｏｓｐｏｒｉｎ　Ａ：　ａ　ｐｉｌｏｔ　ｓｔｕｄｙ' Ｇｒａｅｆｅｓ　Ａｒｃｈ　Ｃｌｉｎ　Ｅｘｐ　Ｏｐｈｔｈａｌｍｏｌ Ｖｏｌ．２３７，　Ｎｏ．５, 1999, ｐ．４３５-８ *
JPN6013026222; ＨＵ，Ｙ．　ｅｔ　ａｌ，　Ｃｏｎｊｕｎｃｔｉｖａｌ　ｉｎ　ｖｉｖｏ　ｃｏｎｆｏｃａｌ　ｓｃａｎｎｉｎｇ　ｌａｓｅｒ　ｍｉｃｒｏｓｃｏｐｙ　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ａｔｏｐｉｃ　ｋｅｒａｔｏｃ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510921A (ja) * 2012-03-22 2015-04-13 ラボラトワール テアＬａｂｏｒａｔｏｉｒｅｓ Ｔｈｅａ シクロスポリンａに基づく水性点眼溶液

Also Published As

Publication number Publication date
CN101835463A (zh) 2010-09-15
EP2190407B1 (en) 2016-12-07
EP2190407A2 (en) 2010-06-02
WO2009099467A3 (en) 2009-10-22
IL204614A0 (en) 2010-11-30
CA2700182A1 (en) 2009-08-13
KR20100091946A (ko) 2010-08-19
MX2010003045A (es) 2010-04-29
BRPI0816995A2 (pt) 2015-03-24
RU2010112472A (ru) 2011-10-27
AU2008349774A1 (en) 2009-08-13
US20080146497A1 (en) 2008-06-19
WO2009099467A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
JP2021075564A (ja) シクロスポリン組成物
JP2010540446A (ja) シクロスポリン組成物
US8906861B2 (en) Pharmaceutical compositions comprising cyclosporins
EP2726060B1 (en) Macrogol 15 hydroxystearate formulations
US20150366799A1 (en) Method of treating allergic conjunctivitis with cyclosporin compositions
AU2022202326A1 (en) Cyclosporin compositions
AU2016203191B2 (en) Cyclosporin compositions
CN101896160A (zh) 环胞菌素组合物
HK1146893A (en) Cyclosporin compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225